Loan Facility

The Loan Facility is the largest measure in the Greek Recovery and Resilience Plan, and its objective is to facilitate private sector financing and supporting private investment.

This is particularly important in Greece where corporate rates remain above the euro area average, and the Loan Facility can constitute a buffer against the negative impact of high market interest rates.

Projects that are being financed concern green transition, digitalization, increasing export capacity, economies of scale through mergers and acquisitions, and innovation (R&D).

DEMO SA Pharmaceutical Industry, established in 1965, is active in developing, producing and marketing of pharmaceutical products. Currently employing over 1.700 employees, it is one of the major pharmaceutical manufacturers in Greece.

The company’s manufacturing plant, located in Kryoneri, Attica, is the largest in Southeastern Europe in the production of injectables, with modern facilities covering 66.000 m2.

The company is currently implementing an investment plan of €356 million that includes the increase of existing production capacity, the R&D and production of chemical APIs and medicines and the R&D and production of biological APIs and medicines.

RRF supports different parts of DEMO’s investment plan, such as, the development of a new Biotechnology Research Center in Attica, the construction of an industrial complex in Tripoli for the production of APIs and final products for hospitals, R&D activities in Thessaloniki, through:

• Loan Facility (ID 16980): € 45.9 million
• Clawback Measure (ID 16816): € 64 million

Facebook channel